FDA Recalls Braga Fresh's Broccoli From Walmart, Deems It a ‘Class I' Risk
The U.S. Food and Drug Administration has now attached its most serious recall category — Class I — to the broccoli from Braga Fresh. It is a Salinas, California-based producer of fresh salad greens and vegetables. These broccolis were distributed at stores in 20 states. This comes after the FDA initiated an initial recall on December 31, 2024, for the washed and ready-to-eat Marketside Broccoli Florets' 12-ounce bags. The agency had learned about the presence of Listeria monocytogenes in several samples taken from a Walmart store in Texas.
The FDA listed Braga Fresh's broccoli from Walmart as a Class I risk in a notice published on January 27, 2024. This has led to Braga Fresh pulling back a single lot of 12-ounce bags of washed and ready-to-eat Marketside Broccoli Florets from the market. The 20 states where the broccoli had been distributed in Walmart branches are Alaska, Arkansas, Arizona, California, Colorado, Idaho, Illinois, Indiana, Kentucky, Louisiana, Michigan, Montana, Nevada, Ohio, Oklahoma, Oregon, Texas, Utah, Washington, and Wyoming.
The packages being recalled have a best-used-by-date of December 10, 2024. Additionally, their UPC is 6 81131 32884 5 and their lot code is BFFG327A6. FDA has advised consumers to throw away the product immediately if they have it at their home.
At the time of this article's composition, no death related to the recall has been reported. However, according to the agency's website, Class I designation means 'a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.'
Listeria monocytogenes is a type of bacteria. It is the most common cause of the infectious and foodborne disease known as Listeriosis. The bacteria thrive in soil, groundwater, rotting vegetation, and animal feces. A person generally develops a case of Listeriosis by ingesting contaminated food. The disease can affect anyone. However, pregnant individuals, people who are aged 65 or older, and developing fetuses are the most vulnerable. Severe cases can potentially result in sepsis, meningitis, encephalitis, permanent health issues, and even death.
The post FDA Recalls Braga Fresh's Broccoli From Walmart, Deems It a 'Class I' Risk appeared first on ComingSoon.net - Movie Trailers, TV & Streaming News, and More.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Canadian doctor after devastating Sudan assignment: 'The worst humanitarian crisis in the world'
Sudan is facing an emergency of staggering proportions, one that has displaced over 12 million people and decimated the nation's healthcare system. But unlike other global crises, this one seems to be happening almost entirely in silence. 'This is not just a war between two parties,' says Sana Bég, executive director of Médecins Sans Frontières (MSF) Canada. 'It's a war on the people of Sudan.' What began as a power struggle between the Sudanese Armed Forces (SAF) and the Rapid Support Forces (RSF) in April 2023 has spiralled into what aid workers now describe as the world's largest displacement crisis. According to the World Health Organization, 70 to 80 per cent of the country's healthcare facilities are either nonfunctional or overwhelmed. In parts of Darfur, even the UN is absent, leaving MSF — also known as Doctors Without Borders — as the only international organization delivering aid on the ground. 'Having to choose between one life-saving activity for another are the kinds of decisions our teams are left to make because of this increasingly isolated environment where we're the only ones being relied on to carry out an entire scope of what should be an ecosystem of aid,' Bég says. This is not just a war between two parties. It's a war on the people of Sudan. For Dr. Reza Eshaghian, a Vancouver-based physician who recently returned from Darfur, the devastation is unlike anything he has seen before. 'What's happening in Sudan is the worst humanitarian crisis in the world, full stop,' he says. 'There are bombings, sexual violence, armed robbery. There's a lack of protection and international humanitarian law.' Eshaghian, who began working with MSF in 2014, was stationed in Nyala, a city in South Darfur. He noted that it's not just the violence itself that is killing people: 'So much of the suffering and death is from preventable illness. We saw women dying from eclampsia and postpartum hemorrhage. People are dying of malaria, malnutrition, diarrhea, dehydration, sepsis. These are things we know how to treat, but there's no infrastructure left to do it.' The hospital Eshaghian helped support saw overwhelming gaps in supplies and staffing. Although MSF brings in its own equipment, the logistics are gruelling, and his team saw supply shipments often delayed. There was also never enough. People are dying of malaria, malnutrition, diarrhea, dehydration, sepsis. These are things we know how to treat, but there's no infrastructure left to do it. Despite the danger, MSF has continued to provide help where it can, but the work has come at immense personal cost, especially for local staff. 'Eighty percent of our workforce globally is locally hired,' Bég notes. 'These are people whose homes are war zones. [They] tell us they have a fear of retaliation or repercussions for any actions that could be interpreted as siding with one warring party or the other. Having to live in fear on a regular basis is far different than what some of our teams that have the ability to get on a plane and leave face.' In other words, simply providing medical care can be seen as a political act. But that doesn't make it any more secure. The safety protocols MSF follows — clearly marked medical uniforms, identified facilities — are no longer a guarantee. 'We used to rely on international humanitarian law to protect aid workers and patients,' she says. 'That's not the reality anymore. Not in Sudan. The sad reality now is that we are no longer able to guarantee safety in the countries that we're operating in, so we're taking it day by day.' Among the most at-risk in Sudan, as is often the case in most war zones, are women and children. In one year alone, MSF supported approximately 8,500 births and performed over 1,600 emergency C-sections across Sudan. 'But the numbers don't tell the full story,' Bég says. 'We're talking about women walking 100 kilometres on foot, often pregnant or with sick children, just to reach care.' Eshaghian recalls one such woman who fled violence in Khartoum and arrived in Nyala with her three-year-old daughter — the last surviving member of her family. 'Her child had a fever. We were able to treat her. But the mother had lost her husband and other children along the way. Everything had been taken from them. And there are endless stories like this one." In many cases, the trauma goes even deeper. MSF staff are seeing widespread evidence of sexual violence being used as a weapon of war. 'Women have been raped while fleeing,' Bég says. 'Survivors end up giving birth to babies born out of rape, then they have to deal with the shame and fear of stigma and retaliation.' The scale of the trauma has pushed MSF to adopt community-based care models that, for example, can look like training trusted women in each village to serve as peer counsellors and connectors to formal care. 'We can't be everywhere,' Bég says. 'But we can empower people to help each other.' Both Bég and Eshaghian say that the world's silence on Sudan is not accidental — it's systemic. 'There are no foreign correspondents in Sudan. No international media,' Bég says. 'We are the eyes to the world, and we see that as a responsibility to speak out about what we're seeing and to call for an urgent scaling of aid.' That lack of visibility means less pressure on governments and organizations like the UN to act. 'UNICEF, UNFPA — their response is small and, in the case of Darfur, they're barely present,' Eshaghian says. 'There's clearly a lack of political and diplomatic pressure from governments who have the power to push for the end of this war.' Bég doesn't mince words. She asks, 'Who gets the privilege of our attention? There are certain conflicts that make it to our feeds, to our social media, to the news. There is an inherent inequity and racism in that itself. Where you live shouldn't determine whether you live, and that is what we're seeing in Sudan — willful ignorance.' Where you live shouldn't determine whether you live. Still, there are reasons to keep going — glimpses of joy, even in the bleakest corners. 'When you visit patients in the hospital, especially children who bounce back from illness and are quite resilient, you see their happiness. [We] took a lot of pride in ... being able to support the community, to see the impact,' Eshaghian says. What MSF is now demanding is clear: A significant increase in humanitarian access, stronger diplomatic pressure on Sudan's warring factions, and more support from countries like Canada. 'Our patients have no choice but to wake up with hope every day,' Bég says. 'The least we can do is show up for them and provide care. Hope is not optional, it's our moral imperative. We have to reject apathy.'
Yahoo
an hour ago
- Yahoo
Health New England to replace Humira coverage with lower-cost biosimilars
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDE Additional applications planned in the US and other markets around the world Not intended for UK-based media DARMSTADT, Germany, June 10, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company's application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. "With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country," said Hong Chow, Head of China and International, Healthcare business of Merck KGaA, Darmstadt, Germany. "Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets." TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease. The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting. About MANEUVERThe pivotal Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21). In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint is objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review in the intent-to-treat (ITT) population. Secondary endpoints include tumor volume score, active range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS). After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of dosing, results of which are expected in mid-2025. Patients who complete Part 2 may then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up. About Pimicotinib (ABSK021)Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib was recently granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with tenosynovial giant cell tumor (TGCT) who require systemic therapy. Pimicotinib has been granted breakthrough therapy designation (BTD) by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck KGaA, Darmstadt, Germany, holds worldwide commercialization rights for pimicotinib. Advancing the Future of Cancer CareAt Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer's deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at About Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to to register for your online, change your selection or discontinue this service. View source version on Contacts Media Relations Phone: +1 (781) 427-4351 Investor Relations Phone: +49 6151 72-3321 Sign in to access your portfolio
